Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of CM082 in Advanced Malignant Solid Tumors
NCT03792958Phase 1Unknown
- Sponsor
- AnewPharma Company, Ltd.
- Start
- Feb 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorolanib in Advanced Malignant Solid Neoplasm (AMSN), sponsored by AnewPharma Company, Ltd. Primary endpoints: Maximum Tolerable Dose at Day 28, Dose-Limiting Toxicity at Day 28 and 1 more. Status: unknown.
02
Drugs
vorolanib
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT03792958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792958.